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Neurobiology of Disease

Overexpression of the Astrocyte Glutamate Transporter
GLT1 Exacerbates Phrenic Motor Neuron Degeneration,
Diaphragm Compromise, and Forelimb Motor Dysfunction
following Cervical Contusion Spinal Cord Injury
Ke Li,1* Charles Nicaise,1,2* Daniel Sannie,1 X Tamara J. Hala,1 Elham Javed,1 Jessica L. Parker,1
Rajarshi Putatunda,1 Kathleen A. Regan,1 Valérie Suain,3 Jean-Pierre Brion,3 Fred Rhoderick,4 Megan C. Wright,5
David J. Poulsen,4 and Angelo C. Lepore1
1

Department of Neuroscience, Farber Institute for Neurosciences, Thomas Jefferson University Medical College, Philadelphia, Pennsylvania 19107,
Neurodegeneration and Regeneration Unit, L’Unité de Recherché en Physiologie Moléculaire–Namur Research Institute for Life Sciences, University of
Namur, B-5000 Namur, Belgium, 3Laboratory of Histology, Neuroanatomy and Neuropathology, Université Libre de Bruxelles, B-1070 Brussels, Belgium,
4Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59812, and 5Department of Biology, Arcadia
University, Glenside, Pennsylvania 19038
2

A major portion of spinal cord injury (SCI) cases affect midcervical levels, the location of the phrenic motor neuron (PhMN) pool that
innervates the diaphragm. While initial trauma is uncontrollable, a valuable opportunity exists in the hours to days following SCI for
preventing PhMN loss and consequent respiratory dysfunction that occurs during secondary degeneration. One of the primary causes of
secondary injury is excitotoxic cell death due to dysregulation of extracellular glutamate homeostasis. GLT1, mainly expressed by
astrocytes, is responsible for the vast majority of functional uptake of extracellular glutamate in the CNS, particularly in spinal cord. We
found that, in bacterial artificial chromosome-GLT1-enhanced green fluorescent protein reporter mice following unilateral midcervical
(C4) contusion SCI, numbers of GLT1-expressing astrocytes in ventral horn and total intraspinal GLT1 protein expression were reduced
soon after injury and the decrease persisted for ⱖ6 weeks. We used intraspinal delivery of adeno-associated virus type 8 (AAV8)-Gfa2
vector to rat cervical spinal cord ventral horn for targeting focal astrocyte GLT1 overexpression in areas of PhMN loss. Intraspinal delivery
of AAV8-Gfa2-GLT1 resulted in transduction primarily of GFAP ⫹ astrocytes that persisted for ⱖ6 weeks postinjury, as well as increased
intraspinal GLT1 protein expression. Surprisingly, we found that astrocyte-targeted GLT1 overexpression increased lesion size, PhMN
loss, phrenic nerve axonal degeneration, and diaphragm neuromuscular junction denervation, and resulted in reduced functional diaphragm innervation as assessed by phrenic nerve-diaphragm compound muscle action potential recordings. These results demonstrate
that GLT1 overexpression via intraspinal AAV-Gfa2-GLT1 delivery exacerbates neuronal damage and increases respiratory impairment
following cervical SCI.
Key words: adeno-associated virus; gene therapy; glutamate transporter; phrenic motor neuron; respiratory; spinal cord injury
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ing in especially severe physical and psychological debilitation.
Chronic respiratory compromise is the leading cause of morbidity and mortality following cervical SCI, and is due to phrenic
motor neuron (PhMN) loss and/or injury to descending bulbospinal respiratory axons (Lane et al., 2008). The major inspiratory
muscle, the diaphragm, is innervated by PhMNs located at midcervical levels C3–C5. Importantly, the majority of these injuries
affect the location of the PhMN pool, and respiratory function
following midcervical SCI is significantly determined by PhMN
loss/sparing (Strakowski et al., 2007).
Contusion-type trauma, the predominant form of SCI observed in the clinical population, is followed by a period of sec-
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ondary cell death and consequent exacerbation of functional
deficits (Oyinbo, 2011). Glutamate-mediated excitotoxicity plays
a key role in these secondary events. Large increases in extracellular glutamate occur shortly after SCI, and elevation can also
persist, depending on injury severity (Panter et al., 1990; Liu et al.,
1991; McAdoo et al., 1999). Early gray matter loss is likely mediated by NMDA receptors, while delayed loss of neurons and oligodendrocytes, as well as axonal and myelin injury, is thought to
be predominantly mediated via AMPA overactivation. Spinal
motor neurons are particularly vulnerable to glutamate excitotoxicity due to such factors as expression of calcium-permeable
glutamate receptors and low calcium-buffering capacities (Xu et
al., 2004, 2008).
Glutamate transporter-1 (GLT1) plays a central role in regulating extracellular glutamate levels. GLT1 is almost exclusively
expressed by astrocytes and accounts for ⬃90% of functional
uptake of extracellular glutamate (Tanaka et al., 1997). Following
SCI, astrocyte death, and/or compromised GLT1 expression,
membrane localization and/or function can result in dysregulation of glutamate homeostasis. Several studies have shown that
GLT1 expression is chronically reduced following thoracic SCI
(Kim et al., 2011; Min et al., 2012). Changes in GLT1 expression
appear to be spatiotemporally regulated in a more subtle manner
(Xu et al., 2008; Gwak et al., 2012). Rapid GLT1 upregulation has
been reported within the first hours post-SCI (Vera-Portocarrero
et al., 2002) in surviving astrocytes (Xu et al., 2008). This increase
may function to counteract immediate elevation of glutamate
during the early phase; however, this initial response is followed
by long-lasting downregulation due to astrocyte death and reduced expression in reactive astrocytes and even in newly generated cells arising from astrocyte proliferation (Xu et al., 2008; Min
et al., 2012). These data suggest that the long-term ability of
astrocytes to regulate extracellular glutamate homeostasis postSCI is compromised, which increases susceptibility to secondary
excitotoxic damage.
Selective GLT1 overexpression in adult astrocytes had previously made it difficult to clearly determine its exact contribution
to neuroprotection following SCI. To this end, we used recombinant adeno-associated viral type 8 (AAV8) vectors to selectively
drive overexpression of GLT1 in astrocytes in a clinically relevant
model of midcervical contusion SCI. Furthermore, we evaluated
key histological and functional outcomes associated with a large
proportion of human SCI, namely PhMN loss, diaphragm denervation, and consequent respiratory dysfunction.

Materials and Methods
Animals
Transgenic bacterial artificial chromosome (BAC)-GLT1-enhanced
green fluorescent protein (eGFP) transgenic mice were previously generated by Regan et al. (2007) and were a kind gift from Jeffrey Rothstein’s
laboratory at Johns Hopkins University. BAC-GLT1-eGFP mice were
used to quantify GLT1 promoter activity following cervical contusion.
Male BAC-GLT1-eGFP mice and wild-type C57BL/6 mice aged from 8 to
12 weeks were used in the study. Female Sprague Dawley rats weighing
250 –300 g were purchased from Taconic Farm. Rats were divided into
three paradigm groups according to the experimental design described
below. All animals were housed in a humidity-controlled, temperaturecontrolled, and light-controlled animal facility under standard chow and
with ad libitum access to water. Experimental procedures were approved
by the Thomas Jefferson University institutional animal care and use
committee and conducted in compliance with the European Communities Council Directive (2010/63/EU, 86/609/EEC, and 87-848/EEC), the
National Institutes of Health Guide for the Care and Use of Laboratory
Animals, and the Society for Neuroscience’s Policies on the Use of Animals in Neuroscience Research.
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Experimental design
Mouse SCI paradigm. BAC-GLT1-eGFP mice were subjected to cervical
contusion SCI at both C4 and C5 levels (Nicaise et al., 2012b), and were
then killed 2, 14, or 42 d postinjury (DPI). Spinal cord tissue was processed for histology to quantify the number of eGFP ⫹ cells in the ventral
horn ipsilateral to the lesion site. Nontransgenic C57BL/6 mice also received C4⫹C5 spinal contusion to measure whole-tissue GLT1 protein
levels by immunoblotting. After the animal was killed, the spinal cord
was freshly removed, subdivided into 1.5-mm-long hemicord fragments
encompassing the epicenter of the injury or spinal cord segments caudal
to the epicenter (Fig. 1C), and then snap-frozen with liquid nitrogen.
Rat SCI paradigm 1. AAV-Gfa2-eGFP or AAV-Gfa2-GLT1 was injected into the spinal cord ventral horn of sham (laminectomy-only uninjured) or spinally contused rats, and rats were then killed 2 or 10 d
postinjection. This preliminary study was used to determine the efficiency of the virus for targeting/transducing spinal cord astrocytes, the
timing of GLT1 overexpression, and the spatial distribution/spread of
virus transduction.
Rat SCI paradigm 2. AAV-Gfa2-eGFP or AAV-Gfa2-GLT1 was injected into the spinal cord ventral horn at the C3, C4, and C5 levels
ipsilateral to the injury site (see Fig. 3A) 10 d before unilateral C4 contusion (see Fig. 5A). Rats were killed 42 DPI. This “pretreatment” paradigm
was aimed at boosting the levels of GLT1 within the spinal cord before
injury as proof of principle. These animals were used for comprehensive
behavioral, electrophysiological, and histological analysis of the therapeutic efficacy of GLT1 overexpression.
Rat SCI paradigm 3. Rats were injured at the C4 level and were then
immediately injected with AAV-Gfa2-eGFP or AAV-Gfa2-GLT1 into
spinal cord ventral horn at the C3, C4, and C5 levels ipsilateral to the injury
site (see Figs. 3A, 8A). This “acute” AAV injection was tested as a more
clinically relevant paradigm of AAV-mediated GLT1 overexpression.

Cervical contusion SCI
Cervical contusion SCI was performed on mice and rats. Mice were
anesthetized with ketamine (120 mg/kg) and xylazine (5 mg/kg). The
dorsal skin and underlying muscle layers were incised and retracted between the spinous processes of C2 and T1. The paravertebral muscles
overlying C4 –C6 were removed. Following right-sided unilateral laminectomy at C4 and C5 levels, mice were subjected to a double spinal
contusion injury with the Infinite Horizon impactor (Precision Systems
and Instrumentation) at both C4 and C5 levels using a 1 mm tip. The
force of both impacts was 50 kdyn (impact on C4 was generated first).
Sham control mice underwent the same surgery, including laminectomy,
but did not receive contusion injury. Rats were anesthetized with ketamine (100 mg/kg), xylazine (5 mg/kg), and acepromazine (2 mg/kg).
The cervical dorsal skin and underlying muscles were incised. The paravertebral muscles overlying C3–C5 were removed. Following unilateral
laminectomy on the right side at C3, C4, and C5 levels, rats were subjected to a C4 spinal contusion injury with the Infinite Horizon impactor
using a 1.5 mm tip at a force of 395 kdyn. These injury paradigms are
based on our previously published mouse (Nicaise et al., 2012b) and rat
(Nicaise et al., 2012a, 2013) models that result in robust PhMN degeneration and chronic diaphragm dysfunction. After surgical procedures in
both mice and rats, overlying muscles were closed in layers with sterile
4-0 silk sutures, and the skin incision was closed using wound clips.
Animals were allowed to recover on a circulating warm-water heating
pad until awake and then returned to their home cages. They were monitored daily until they were killed, and measures were taken to avoid
dehydration and to minimize any pain or discomfort. No signs of bladder
or bowel dysfunction were ever detected following injury.

Virus production and delivery
Two recombinant AAV8 vectors carrying eGFP or GLT1 driven by the
Gfa2 promoter were constructed to specifically target astrocytes. The
viral vectors were prepared as previously described (Weller et al., 2008).
Recombinant AAV8 was packaged in HEK293T cells. Approximately
1.5 ⫻ 10 7 cells were seeded into 150 cm dishes in DMEM supplemented
with 10% FBS, 1 mM MEM sodium pyruvate, 0.1 mM MEM nonessential
amino acids, and 0.05% penicillin-streptomycin (5000 U/ml). At 24 h
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after cell seeding, medium was changed to culture medium containing only 5% FBS, and
cells were transfected with three plasmids: adeno helper plasmid ( pF⌬6), AAV helper encoding serotype 8 (kindly provided by Miguel
Sene Esteves at the University of Massachusetts), and the AAV packaging vector containing the glial fibrillary acidic protein (GFAP)
promoter flanked by either the eGFP gene or
the human EAAT2 (GLT1a) gene sequence
(obtained from Jeffrey Rothstein’s laboratory).
Plasmids were transfected into HEK293T cells
using Polyfect according to the manufacturer’s
specifications (Qiagen). Cultures were incubated at 37°C in 95% O2 and 5% CO2. After
72 h, cells were harvested and pelleted by centrifugation. The pellet was resuspended in 10
mM Tris, pH 8.0, and chilled on ice. Cells were
lysed by repeated freeze–thaw cycles, followed
by treatment with 50 U benzonase (Novagen)
and 0.5% sodium deoxycholate for 30 min at
37°C. The lysate was sonicated three times. Virus was then purified by density gradient centrifugation in iodixanol according to the
method of Zolotukhin et al. (1999). Each virus
preparation was sterile filtered, and the titer
(genomic particles/ml) was determined by
quantitative RT-PCR using primers and a
probe specific for the woodchuck posttranscriptional regulatory element sequence.
Virus delivery was conducted on deeply
anesthetized rats. Following unilateral rightsided laminectomy, three injections, each conFigure 1. Cervical-contusion SCI resulted in both early and chronic downregulation of GLT1 promoter activity and protein
taining 1 l of virus (titer of 10 13 genomic
expression. A, D, In sham uninjured BAC-GLT1-eGFP reporter mice, GLT1 promoter activity, detected by eGFP expression,
particles/ml), were administered in the spinal
was observed in gray matter and to a lesser extent in white matter. D, Inset, Most eGFP ⫹ cells displayed an astrocyte-like
cord ventral horn at levels C3, C4, and C5 using
morphology. B, C, Cervical contusion (B) was induced in BAC-GLT1-eGFP or wild-type C57BL/6 mice at C4 and C5 levels (C,
a Hamilton gas-tight syringe mounted on an
target symbols). C, Mice were killed at multiple time points, and spinal cord was processed for GLT1-eGFP histological
electronic UMP3 micropump (World Precianalysis at specific distances from the lesion epicenter or for GLT1 Western blotting (WB) in whole-tissue homogenate
sion International; Lepore and Maragakis,
subdissected from specific hemicord locations. B, E, Representative BAC-GLT1-eGFP spinal cord images illustrate injury
2011; Lepore, 2011). As shown in Figure 3A,
epicenter following cervical contusion. F, GLT1-eGFP expression in ipsilateral ventral horn (VH) was reduced from day (D)
the sites of injections were targeted along the
2 to D42 at the epicenter. G, H, Locations 1.5 mm rostral and caudal to the epicenter were also examined in uninjured (G)
rostral– caudal axis with a virtual line connectand injured (H ) mice. I, Quantification of eGFP ⫹ cells showed a significant decrease in GLT1-eGFP ⫹ cells at D2 and D42 for
ing the points of dorsal root entry (dotted line)
1.5 mm rostral and D2 for 1.5 mm caudal. J, No changes in eGFP expression were noted at more distant regions at 3.0 mm
and in the lateral axis corresponding to the
from epicenter. Intraspinal GLT1 protein levels were quantified in nontransgenic mice by immunoblotting of freshly
middle of each spinal segment (C3, C4, or C5).
dissected tissue from epicenter and caudal regions (C) in sham and injured mice. K, At multiple time points postinjury, GLT1
Ventral horns were targeted by lowering the 33
protein levels at the epicenter were reduced compared with sham animals. L, Quantification of GLT1 bands normalized to
gauge 45° beveled needle 1.5 mm below the
actin [expressed in arbitrary units (a.u.)] confirmed the loss of intraspinal GLT1 expression at the epicenter. M, No changes
dorsal surface of the spinal cord. Each injection
in GLT1 expression at any time point in the caudal region were detected by immunoblotting. Results were expressed as
was delivered at a constant rate over 5 min.
means ⫾ SEM. *p ⬍ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001 sham versus D2, D14, or D42. n ⫽ 7 mice for sham, D14, and D42
Upon completion of virus delivery, a synthetic
groups; n ⫽ 6 mice for D2.
biocompatible membrane (BioBrane, UDL
Laboratories) was placed on the top of lamiTissue processing for histology
nectomy, which allowed for easy access to the spinal cord below the
At the time the animals were killed, they were anesthetized, and dialaminectomy during the subsequent spinal contusion surgery (in experimental rat paradigm 2). Overlying muscles were then closed in layers
phragm muscle and phrenic nerves were freshly removed before parawith sterile 4-0 silk sutures, and the skin incision was closed using sterile
formaldehyde perfusion and then further processed for nerve
wound clips. Animals were allowed to recover and monitored daily.
histology and neuromuscular junction (NMJ) labeling. Animals were
transcardially perfused with 0.9% saline, followed by 4% paraformalRetrograde anatomical tracing of phrenic motor neurons
dehyde infusion. Spinal cords were harvested, then cryoprotected in
Two weeks before the rats were killed, cholera toxin beta fragment (CT␤)
30% sucrose for 3 d and embedded in freezing medium. Spinal cord
conjugated to Alexa555 (Life Technologies) was injected unilaterally into
tissue blocks were cut serially in the sagittal or transverse planes at a
the intrapleural space of the ipsilateral hemidiaphragm muscle (Nicaise
thickness of 30 m. Sections were collected on glass slides and stored
et al., 2012a). This procedure allowed for the specific labeling of PhMNs
at ⫺20°C until analysis. Spinal cord sections were thawed, allowed to
innervating the diaphragm through retrograde transport of CT␤ fluoresdry
for 1 h at room temperature, and stained with 0.5% cresyl violet

l
of
CT
␤
(0.2%
cent tracer. Following laparotomy under anesthesia, 15
acetate according to standard procedure (Nicaise et al., 2012a). For
solution in distilled water) was intrapleurally delivered through the diaCT␤ and eGFP cell counting, frozen spinal cord sections were airphragm (three injections of 5 l each) using a 20 l Hamilton syringe
dried, washed, and coverslipped with fluorescent-compatible mountwith an attached 33 gauge needle. Abdominal muscles were then sutured
ing medium (ProLong Gold, Life Technologies).
with 4-0 sutures, and skin was closed with wound clips.
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Phrenic nerve histology
Phrenic nerves were processed as previously described (Kim et al., 2011).
Upon removal, phrenic nerves were fixed in 4% glutaraldehyde solution
for 1.5 h, thoroughly washed in Millonig’s buffer with 0.5% (w/v) glucose
for 24 h, postfixed in 2% (w/v) OsO4 for 30 min, dehydrated, and embedded in Epoxy resin LX112. Semithin cross sections (1–2 m thickness) were obtained and stained with 1% toluidine blue (Sigma-Aldrich)
diluted in 2% sodium borate solution. The total nerve area and the total
number of axons and their cross-sectional areas were assessed by two
investigators (T.J.H. and C.N.) in a blind manner using ImageJ software,
as previously reported (Leroy et al., 2007).

NMJ analysis
Fresh hemidiaphragm muscle was dissected from each animal for wholemount immunohistochemistry, as described previously (Wright and
Son, 2007). Animals that did not receive CT␤ injections were used for
this study to avoid overlap of Alexa555-conjugated CT␤ with the
rhodamine-conjugated ␣-bungarotoxin used to label the nicotinic acetylcholine receptors. To enable antibody penetration, muscle was
stretched, pinned down to Sylgard medium (Fisher Scientific), and extensively cleaned to remove any connective tissue. Motor axons and their
terminals were labeled with SMI-312R (Covance) and SV2-s (Developmental Studies Hybridoma Bank), respectively, and both primary antibodies were detected with fluorescin isothiocyanate-conjugated (FITC)
anti-mouse IgG secondary antibodies (Jackson ImmunoResearch Laboratories). Postsynaptic acetylcholine receptors were labeled with
rhodamine-conjugated ␣-bungarotoxin (Life Technologies). Labeled
muscles were analyzed for total numbers of NMJs, fully innervated
NMJs, partially denervated NMJs, completely denervated NMJs, NMJs
with thin preterminal axons, and multiply-innervated NMJs. The latter
two are indicative of motor axon regeneration. Whole-mounted diaphragms were imaged on a FluoView FV1000 confocal microscope
(Olympus).

Immunohistochemistry
Frozen spinal cord sections were air-dried, washed, permeabilized with
0.4% Triton X-100 in PBS for 5 min at room temperature, and then
incubated in blocking solution (PBS containing 10% normal goat serum
and 0.4% Triton X-100) for 1 h at room temperature. Sections were
labeled overnight at 4°C with the primary antibodies in blocking solution. Sections were then washed three times with PBS (5 min per wash)
and incubated with secondary antibodies in blocking solution for 1 h at
room temperature. After washing twice with PBS (10 min per wash),
sections were coverslipped. A number of primary antibodies were used.
Mouse anti-GFAP (1:200; EMD Millipore) and rabbit anti-GFAP (1:200;
Dako North America) were used to label astrocytes (Lepore et al., 2008a).
Rabbit anti-Olig2 (1:200; EMD Millipore) was used to label cells of the
oligodendrocyte lineage (Lepore et al., 2008a). Mouse anti-NeuN (1:100;
EMD Millipore) was used to label neurons (Lepore and Fischer, 2005).
Rabbit anti-His (1:50; Cell Signaling Technology) labeled the His-tag
fused to GLT1 protein. Rabbit anti-GLT1 (1:800) and mouse anti-GLT1
(1:200) were used to label GLT1 protein (both were provided by Jeffrey
Rothstein’s laboratory; Lepore et al., 2008b). Rabbit anti-Ki67 (1:200;
Thermo Fisher Scientific) labeled proliferating cells (Lepore et al.,
2008a). Secondary antibodies included FITC goat-anti-mouse IgG, FITC
goat-anti-rabbit IgG, tetramethylrhodamine isothiocyanate (TRITC)
goat-anti-mouse IgG, TRITC goat-anti-rabbit IgG, Alexa Fluor 647 goatanti-mouse IgG, Alexa Fluor 647 goat-anti-rabbit IgG. All secondary
antibodies were purchased from Jackson ImmunoResearch Laboratories
and diluted at 1:200 to recognize the matched primary antibody.

Imaging and quantification
Images were acquired with either a Zeiss Imager M2 upright microscope
or a FluoView FV1000 confocal microscope (Olympus) and then analyzed with ImageJ or MetaMorph software. In SCI paradigms, lesion size
was quantified in cresyl violet-stained sections (Nicaise et al., 2012a).
Specifically, lesion area was determined in every fifth section by tracing
both the total area of the hemispinal cord ipsilateral to the contusion site
and the actual lesion area. Lesion was defined as areas including both lost
tissue (cystic cavity formation) and surrounding damaged tissue in
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which the normal anatomical structure of the spinal cord was lost. The
lesion epicenter was defined as the section with the largest percentage
lesioned tissue (relative to total tissue area in the same section). Lesion
volume was determined using the Cavalieri estimator of volume (V ⫽
[⌺(A1 ⫹ A2 ⫹ … An) ⫻ D] ⫺ [Amax ⫻ Y], where A is the area of the lesion,
D is the distance between measurements (150 m), and Y is the thickness
(30 m) of each section). Ventral horn motor neurons were outlined in
these same cresyl violet-stained sections, and the number of motor neuron cell bodies was quantified in a blind manner. Large motor neurons
with a clearly identifiable nucleus and a cell soma ⬎200 m 2 (Lepore et
al., 2011b) or medium-sized neurons (150 –200 m 2) were counted.
CT␤ ⫹ PhMN motor neurons were counted in every fifth section across
the entire cervical spinal cord and plotted at specific distances relative to
the lesion epicenter (Nicaise et al., 2013).
In BAC-GLT1-eGFP mice, eGFP ⫹ cells were identified in the ventral
horn using MetaMorph software (Molecular Devices). Cells were
counted and plotted at specific distances relative to lesion epicenter (i.e.,
1.5 and 3.0 mm from the epicenter in both rostral and caudal directions;
Lepore et al., 2011a). To quantify GFAP fluorescence signal in the ventral
horn, integrated intensities were measured in MetaMorph. GFAP intensity was calculated to be the GFAP-integrated intensity minus the
background-integrated intensity of the ventral horn. All GFAP images
were acquired using the same exposure settings. In uninjured sham or
injured rats injected with AAV-Gfa2-eGFP, numbers of eGFP ⫹ cells and
rostral– caudal spreading of virus transduction were similarly analyzed
along the length of the cervical spinal cord.
For in vivo astroglial scar border formation analysis, following immunostaining with mouse anti-GFAP antibody, 3– 4 images per animal (at
locations surrounding the injury epicenter) were obtained at 5⫻ magnification. GFAP ⫹ astroglial processes immediately adjacent to the lesion,
oriented parallel to the border of lesion, and intertwined and overlapped
extensively were regarded as the mature border of the astroglial scar
(Wanner et al., 2013). Quantification results are presented as the percentage of astroglial scar border length compared with the length of total
lesion border.

GLT1 immunoblotting
Whole-tissue spinal cord samples (1.5 mm length) were homogenized on
ice in 0.5 ml of radioimmunoprecipitation assay buffer containing the
following (in mM): 50 Tris-HCl, pH 7.6, 150 NaCl, 2 EDTA, 0.1% SDS,
0.01% NP-40, Protease Inhibitor Cocktail (Roche Diagnostics). Equal
amounts of protein (determined by Bradford assay) were resolved by
SDS-PAGE on 4 –12% gels and transferred to nitrocellulose membranes.
The membranes were blocked in Odyssey blocking buffer (Li-Cor) for 1 h
at room temperature and probed with anti-GLT1 antibody (1:5000) or
anti-actin antibody (1:2000; Abcam) overnight followed by incubation
with IRDye-conjugated goat-anti-rabbit or goat-anti-mouse IgG (1:
10,000; Li-Cor) as secondary antibody for detection. Acquisition was
conducted on a Li-Cor Odyssey infrared imaging system. GLT1 bands
were quantified with ImageJ software by integrating band intensity followed by normalization to actin (Lepore et al., 2011c).

Functional glutamate uptake assay
Glial-restricted precursor (GRP) cells were cultured in differentiation
medium consisting of GRP basal medium supplemented with 10 ng/ml
BMP4 and lacking the mitogen bFGF (Davies et al., 2008) for 2 d and then
infected with AAV-Gfa2-eGFP or AAV-Gfa2-GLT1. After 6 d in culture
postinfection, glutamate uptake activity of GRP-derived astrocytes was
measured, as previously described (Dowd and Robinson, 1996), with
slight modification. Briefly, cells were washed and preincubated with
either a sodium-containing or choline-containing uptake buffer [containing (in mM) the following: 5 Tris, 10 HEPES, 140 NaCl or choline
chloride, 2.5 KCl, 1.2 CaCl2, 1.2 MgCl2, 1.2 K2HPO4, 10 glucose] for 20
min at 37°C; and in dihydrokainate (DHK) treatment groups, 100 M
DHK was added to inhibit GLT1. The uptake buffer was then replaced
with fresh uptake buffer containing 20 nM 3H-glutamate (49 Ci/mmol;
PerkinElmer) and 2 M unlabeled glutamate. The cells were incubated
for 5 min at 37°C. The reaction was terminated by washing cells three
times with ice-cold uptake buffer containing 2 mM unlabeled glutamate,
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followed by immediate lysis in ice-cold 0.1N NaOH. Cell extracts were
then measured with a liquid scintillation counter (Beckman Instruments). The protein content in each well was measured using the Bradford protein assay (Bio-Rad).

In vitro scratch-wound assay
GLT1-overexpressing GRPs and wild-type GRPs, which both expressed
GFP, were induced to differentiate into astrocytes with 10 ng/ml BMP-4.
Astrocytes were cultured until confluent (10 –14 d after plating). Scratch
wounds were made as described previously (Nishio et al., 2005). Briefly,
confluent cultures were scratched with a plastic pipette tip according to a
preset grid to induce traumatic injury along the scratch wound. Culture
dishes were washed twice with fresh DMEM to remove the debris and
incubated with fresh medium for 24 h. The cells were then fixed, and
immunostaining was performed with rabbit anti-Ki67 (1:200; Thermo
Fisher Scientific) and mouse anti-GFAP (1:200; EMD Millipore) antibodies. Individual images (5–7 per scratch wound) were obtained at 10⫻
magnification and then analyzed for cell-free area (in mm 2 per field),
migrating cell numbers at various distances (D ⬍ 150 m or D ⬎ 150
m), proliferating cell numbers surrounding the wound site (using Ki67
as the proliferation marker), and lengths of migrating-cell processes (visualized with the GFP tag).

Cylinder paw preference test
All behavioral measurements were conducted on rats starting 2 weeks
before injury and thereafter on a weekly basis until they were killed. Rats
were weekly video-recorded while rearing freely in a transparent cylinder
for 5 min. This test uses spontaneous rearing and exploratory behavior to
test forelimb asymmetries under a preference paradigm. Three behaviors
were scored during vertical exploration: use of the right ipsilateral forelimb alone, use of the left contralateral forelimb alone, and use of both
forelimbs simultaneously. The hit score was expressed as a percentage of
usage of each forelimb to total limb usage (Nicaise et al., 2012a).

Grip strength test
Muscle grip strength was weekly determined for the ipsilateral (right)
forelimb using a “grip strength meter” (DFIS-2 Series Digital Force
Gauge; Columbus Instruments). Grip strength testing was performed by
allowing the rat to grasp a thin bar attached to the force gauge. This was
followed by pulling the animal away from the gauge until the forelimb
released the bar. The force measurements were averaged from three trials
(Nicaise et al., 2012a).

Diaphragm compound muscular action potentials and
spontaneous EMG recordings.
Rats were anesthetized in the same manner described above. Phrenic
nerve conduction studies were performed with single stimulation (0.5 ms
duration; 6 mV amplitude) at the neck via near nerve needle electrodes
placed along the phrenic nerve (Lepore et al., 2010). The ground needle
electrode was placed in the tail, and the reference electrode was placed
subcutaneously in the right abdominal region. Recording was obtained
via a surface strip along the costal margin of the diaphragm, and compound muscular action potential (CMAP) amplitude was measured
baseline to peak. Recordings were made using an ADI Powerlab 8/30
stimulator and BioAMP amplifier (ADInstruments), followed by
computer-assisted data analysis (Scope 3.5.6, ADInstruments). For each
animal, 10 tracings were averaged to ensure reproducibility.
Before being killed, animals were anesthetized and received a laparotomy. Bipolar electrodes 3 mm apart were inserted into several locations
in the right hemidiaphragm (Nicaise et al., 2012a). The EMG signal was
amplified, filtered through a bandpass filter (50 –3000 Hz), and integrated
(dV ⫻ dt) using LabChart 7 software (AD Instruments). Parameters, such as
respiratory bursts per minute, burst duration, and integrated EMG peak
amplitude, were averaged over 2 min sample periods.

Statistics

Results were expressed as means ⫾ SEM. A Kolmogorov–Smirnov test was
conducted for all variables to assess normality. Unpaired t test or Mann–
Whitney was used to assess statistical significance between two groups. With
respect to multiple comparisons involving ⱖ3 groups, statistical significance

was assessed by one-way ANOVA followed by post hoc test (Bonferroni’s
method). Statistics were computed with Graphpad Prism 5 (GraphPad Software). p ⬍ 0.05 was considered as statistically significant.

Results
Cervical contusion SCI resulted in both early and chronic
downregulation of GLT1 promoter activity and protein
expression
Using BAC-GLT1-eGFP transgenic promoter reporter mice, we
spatially and temporally characterized the promoter activity of
astrocyte GLT1 following unilateral cervical contusion SCI. In
uninjured control mice, GLT1 promoter activity, as detected by
eGFP ⫹ cells, was abundantly observed in gray matter and to a
lesser extent in white matter (Fig. 1A). At 2 DPI, contused spinal
cords showed a disruption of spinal cord architecture, including
significant loss of eGFP ⫹ astrocytes at the lesion epicenter (Fig.
1B), compared with uninjured animals (Fig. 1A). Highermagnification views (Fig. 1 D, E) of the ventral horn were used to
quantify individual eGFP ⫹ cells at specific distances from the
epicenter, as illustrated in Figure 1C. We confirmed that a significant decrease in GLT1 promoter activity occurred as early as 2
DPI in sham versus injured mice ( p ⬍ 0.001) and persisted to 14
and 42 DPI ( p ⬍ 0.001) at the epicenter (Fig. 1F ). We next
analyzed spinal cord segments rostral (Fig. 1G,H ) and caudal to
the epicenter, locations where overt tissue disruption was not
observed. In spinal cord ipsilateral to the lesion, the numbers of
eGFP ⫹ cells 1.5 mm both rostral and caudal to epicenter were
also significantly lower at 2 DPI (Fig. 1I; p ⬍ 0.05). Although
significant at only the later time point of 42 DPI (Fig. 1I; p ⬍
0.05), there were trends toward decreased numbers of eGFP ⫹
cells at 1.5 mm both rostrally at 14 DPI and caudally at 42 DPI
compared with time-matched uninjured controls. When analyzed at the greater distance of 3.0 mm rostral and caudal to the
epicenter, the numbers of eGFP ⫹ cells did not differ statistically
between injured and uninjured mice at any time point (Fig. 1J ).
To complement these histological studies, we also correlated
the downregulation of promoter activity with intraspinal GLT1
protein expression levels using immunoblotting on whole-tissue
homogenate subdissected from various spinal cord segments
(Fig. 1C). GLT1 protein was highly expressed in uninjured spinal
cord, while its expression was significantly reduced following cervical contusion (Fig. 1K ). At the epicenter, quantification of
GLT1 immunoblotting showed ⬃50 – 80% downregulation at
2– 42 DPI compared with uninjured control (Fig. 1L). GLT1 protein expression at a spinal cord segment (C6) caudal to the epicenter was not different when comparing injured and uninjured
animals (Fig. 1M ). Collectively, these results demonstrate that
the numbers of GLT1-expressing astrocytes in ventral horn and
overall intraspinal GLT1 protein expression were reduced soon
after C4-contusion SCI injury and that the decrease persisted
chronically for ⱖ6 weeks.
Lack of GLT1 expression in proliferating, reactive astrocytes
following cervical contusion SCI
We next examined changes in the phenotype of astrocytes using
markers of astrocyte reactivity (GFAP) and cell proliferation
(Ki67) after cervical contusion SCI. Again using BAC-GLT1eGFP transgenic mice, we correlated these immunohistochemical findings with GLT1 promoter activity. Astrocyte reactivity
caused by injury results in robustly increased GFAP expression.
In the intact spinal cord, gray matter astrocytes express levels of
GFAP protein that are nearly undetectable using immunohistochemistry; therefore, GFAP analysis is an established approach
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Figure 2. Lack of GLT1 expression in proliferating, reactive astrocytes following cervical-contusion SCI. A, C, Immunohistochemistry for GFAP and Ki67 was analyzed in the ventral horn at
epicenter (A) and rostral (C) locations at day (D) 2, D14, and D42 postinjury. Sham, Laminectomy-only uninjured mice. B, D, Quantification of GFAP immunofluorescence intensity and Ki67 ⫹ cell
numbers is shown for epicenter (B) and rostral (D) ventral horn locations. Results are expressed as means ⫾ SEM. *p ⬍ 0.05, **p ⬍ 0.01 sham versus D2, D14, or D42. n ⫽ 6 mice in sham and D2
groups; n ⫽ 7 in D14 and D42 groups. E, F, Confocal images of immunostaining for GFAP/Ki67 in the ventral horn of uninjured BAC-GLT1-eGFP mice (E) and injured spinal cord at D14 (F). E, Arrowheads,
GFAP/eGFP colocalization in the uninjured spinal cord. F, Left, Arrowheads, GFAP/Ki67 colocalization in the injured spinal cord, demonstrating extensive astrocyte proliferation. F, Center, Arrowheads, Small
percentage of GFAP/eGFP colocalization following injury, despite the increased number of GFAP ⫹ astrocytes. F, Right, Proliferating astrocytes did not express GLT1. VH, Ventral horn.

for histologically quantifying astrocyte reactivity at specific anatomical locations. As demonstrated by increased GFAP immunofluorescence intensity, astrocytes displayed dramatic reactivity in
the ipsilateral ventral horn starting at 14 and 2 DPI at the lesion
epicenter (Fig. 2 A, B) and in intact rostral spinal cord (Fig. 2C,D),
respectively, and reactivity persisted to 42 DPI. This reactive astrocyte response was associated with marked increases in the
numbers of actively proliferating Ki67 ⫹ cells in the ventral horn
at both the lesion epicenter (Fig. 2 A, B) and rostral spinal cord
(Fig. 2C,D) at multiple time points postinjury.
We conducted confocal analysis to characterize changes in the
phenotype of individual astrocytes following injury in the context
of GLT1 expression and proliferation. In uninjured BAC-GLT1eGFP cervical spinal cord, nearly all GFAP-positive astrocytes
expressed GLT1 (Fig. 2E), which coincides with the robust and
mostly astrocyte-specific expression of GLT1 in the CNS (Regan
et al., 2007). Following cervical-contusion SCI, there was a pronounced reactivity of astrocytes in the ventral horn (both at the
lesion epicenter and in intact rostral spinal cord) at all time points
characterized by significantly increased expression of GFAP in
individual astrocytes, as well as an increase in the total numbers
of astrocytes (Fig. 2F ). Following injury, there was also a large
increase in the number of total proliferating cells in the ventral
horn at epicenter and rostral locations, as assessed with Ki67 (Fig.

2F ). A significant percentage of these Ki67 ⫹ cells were GFAP ⫹
cells (Fig. 2F ), suggesting that astrocyte proliferation at least partially accounted for the increase in number of astrocytes postinjury. Importantly, despite this increase in the number of GFAP ⫹
cells, the majority of reactive astrocytes following injury (proliferating astrocytes and/or nondividing astrocytes that have increased GFAP expression) did not express GLT1 (Fig. 2F ).
Collectively, these results show that astrocytes of the ventral
horn become reactive very early following cervical contusion SCI
and remain chronically in a reactive state. In addition, a large
portion of the astrocyte population proliferates, particularly with
proximity to the site of injury. Despite this robust response that
can result in an increase in the number of astrocytes, these reactive cells were compromised in GLT1 expression following cervical SCI, suggesting an inability to properly regulate extracellular
glutamate homeostasis.
Intraspinal AAV-mediated gene delivery resulted in
overexpression of normally functioning GLT1 without
inducing motor neuron loss or phenotypic impairment
To investigate whether overexpression of exogenous GLT1 in
astrocytes protects PhMNs against glutamate excitotoxicity following cervical-contusion (C4) SCI in rats, we intraspinally delivered the GLT1-His fusion gene or eGFP gene using AAV-Gfa2
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Figure 3. Transduction, functional glutamate uptake, and lack of cytotoxicity following intraspinalAAV-mediatedgenedelivery.A,AAV-Gfa2-eGFPorAAV-Gfa2-GLT1wasintraspinallyinjectedinto
ventralhornofratsatC3,C4,andC5levels.B,At10dpostinjection(butnotat2d),His-GLT1expression
was detected in spinal cord with immunostaining for His-tag. C, eGFP signal was detected as the
reporter for AAV8 transduction and exogenous gene expression. C, Inset, Astrocyte morphology of
Gfa2-eGFP ⫹ cells.D,QuantificationofeGFP ⫹ cellnumbersatrostral– caudaldistancesfromasingle
injection site in spinal cord white matter and gray matter. E, F, AAV-Gfa2-eGFP, AAV-Gfa2-GLT1, or
artificial CSF (aCSF) as the control was intraspinally injected into uninjured spinal cord, and motor
neuron numbers surrounding the injection site (E) and phrenic nerve CMAP amplitudes (F) were
measured at day (D) 10 postinjection to determine whether AAV injection itself or GLT1 overexpression caused histological damage and/or function loss. Results are expressed as means ⫾ SEM. n ⫽ 3
ratsineachgroup.G,ImmunocytochemistryforGFAPandGLT1oninvitroculturedastrocytesshowed
lack of GLT1 protein expression following AAV-Gfa2-eGFP infection, while GLT1 was highly expressed
in nearly all AAV-Gfa2-GLT1-infected astrocytes. H, 3H-glutamate uptake assay was performed on in
vitro cultured astrocytes following infection with AAV-Gfa2-eGFP or AAV-Gfa2-GLT1. AAV-Gfa2-GLT1
transduction significantly increased levels of sodium-dependent glutamate uptake in astrocytes,
which could be blocked by the GLT1 inhibitor, DHK. Results were expressed as means ⫾ SEM. *p ⬍
0.05, **p ⬍ 0.01, n ⫽ 3 duplicates for each group.

vectors that drive expression under control of the astrocyte GFAP
promoter (Fig. 3A).
We first temporally assessed the time course of exogenous
His-GLT1 expression at days 2 and 10 postinjection into the un-
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injured spinal cord, and found robust expression of His-tagged
GLT1 protein in the ventral horn at day 10 postinjection, but
little-to-no expression at day 2 (Fig. 3B). We injected AAV-Gfa2eGFP or AAV-Gfa2-GLT1 into the injured spinal cord 10 d before
unilateral C4 contusion, and we then examined the efficiency and
location of transduction by the AAV-Gfa2 vector by detecting
eGFP reporter distribution in the cervical spinal cord at day 10
postinjury. Expression of exogenous gene delivered by AAV-Gfa2
vector was highly localized to ventral gray matter, with significant
transduction also observed in white matter close to the gray–
white matter interface (Fig. 3 B, C). The majority of eGFP-labeled
cells possessed an astrocyte-like morphology (Fig. 3C, inset).
eGFP ⫹ cell counting showed that transduced cells were robustly
distributed from ⬃3 mm rostral to 3 mm caudal to a single injection site in both gray and white matter (Fig. 3D).
Although previous reports have shown that exogenous gene
expression from AAV is nontoxic (Ponnazhagan et al., 1997; Monahan et al., 2002), we tested potential in vivo cytotoxicity in our
experimental paradigm. AAV-Gfa2-GFP or AAV-Gfa2-GLT1
(10 13 genomic particles/ml), or artificial CSF as the control, was
injected into ventral horn of the C4 spinal cord of uninjured rats.
At day 10 postinjection, we conducted total motor neuron counts
and phrenic nerve-diaphragm CMAP recordings, an in vivo electrophysiological assessment of functional diaphragm innervation
by PhMNs (Lepore et al., 2010). There were no significant differences among the three groups in either ventral horn motor neuron
numbers across the cervical spinal cord (Fig. 3E) or peak CMAP
amplitudes (Fig. 3F), demonstrating that AAV injection itself and
AAV-based GLT1 overexpression are not toxic in the spinal cord.
To assess the functional glutamate uptake capability of astrocytes transduced with virus, we performed an 3H-glutamate uptake assay on cultured astrocytes derived from glial-restricted
precursors (a class of lineage-restricted astrocyte progenitor cells;
Lepore et al., 2006), which were infected with AAV-Gfa2-eGFP or
AAV-Gfa2-GLT1. Nearly all cells in both culture conditions were
differentiated GFAP ⫹ astrocytes (Fig. 3G). GLT1 protein expression was not detected in AAV-Gfa2-eGFP infected cells, which is
expected in astrocytes cultured without neurons also present
(Yang et al., 2009), while GLT1 was highly expressed in nearly all
AAV-Gfa2-GLT1 astrocytes (Fig. 3G). Furthermore, GLT1 overexpression following AAV-Gfa2-GLT1 transduction significantly
increased levels of sodium-dependent glutamate uptake in astrocytes (121.6 ⫾ 6.4 vs 190.2 ⫾ 24.4 cpm/g protein, p ⬍ 0.01),
which could be blocked by 100 M of the GLT1 inhibitor, DHK
( p ⬍ 0.05; Fig. 3H ).
Collectively, these results demonstrate that AAV delivery resulted in efficient in vivo transduction and expression of GLT1
protein throughout the cervical spinal cord, did not result in
neuronal injury or functional diaphragm impairment, and increased the capacity of astrocytes for functional GLT1-mediated
glutamate uptake.
Intraspinal AAV-mediated gene delivery resulted in
exogenous GLT1 overexpression specifically in astrocytes
We performed double immunostaining for GLT1 and His-tag,
which is fused to the N terminus of GLT1, to distinguish exogenous from endogenous GLT1 protein in the injured spinal cord.
His-tag colocalized with GLT1 (Fig. 4A, inset), and the His-tag ⫹
area showed greater GLT1 immunofluorescence signal than
nearby locations containing only endogenous GLT1 expression
(Fig. 4A, arrowheads). Immunoblotting of whole-tissue spinal
cord homogenate confirmed that total GLT1 protein expression
levels in the injured spinal cord were significantly increased in the
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Figure 4. Intraspinal AAV-mediated gene delivery resulted in exogenous GLT1 overexpression specifically in astrocytes. A, Double immunohistochemistry for His-tag and GLT1 showed that the His-tag
colocalizedwithGLT1protein(arrowheadsdenotedouble-labeledcells).Insertsshowhighermagnification.B,QuantificationofGLT1immunoblottingshowsthatGLT1proteinexpressionlevelsinthespinalcord
were increased with AAV-Gfa2-GLT1. C, Double immunohistochemistry for His-tag and GFAP showed that exogenously expressed GLT1 colocalized with GFAP ⫹ astrocytes (arrowheads denote double-labeled
cells). D, Immunohistochemistry for GFAP (astrocytes), Olig2 (oligodendrocyte lineage), and NeuN (neurons) on spinal cord confirmed that AAV transduction was mainly restricted to GFAP ⫹ astrocytes
(arrowheadsdenotedouble-labeledcells).E,PercentageofeGFP ⫹ cellscoexpressingGFAP,Olig2,orNeuNinboththeuninjuredandinjuredventralhorn.F,High-magnificationconfocalimagesshowthateGFP
was highly colocalized with GFAP, but not with Olig2 or NeuN. Results were expressed as means ⫾ SEM. *p ⬍ 0.05 AAV-Gfa2-GLT1 group versus AAV-Gfa2-eGFP group; n ⫽ 5 rats per group.

AAV-Gfa2-GLT1 group compared with AAV-Gfa2-eGFP control ( p ⬍ 0.05; Fig. 4B). Double immunostaining for GFAP and
His-tag demonstrated that exogenous His-GLT1 was mainly expressed in GFAP ⫹ astrocytes (Fig. 4C, arrowheads). To further
quantify the phenotypic identity of transduced cells in the spinal
cord, we performed immunostaining for the lineage-specific
markers GFAP (astrocytes), Olig2 (cells of the oligodendrocyte
lineage), and NeuN (neurons) in both the uninjured (Fig. 4D)
and injured (images not shown) spinal cord at day 10 following
AAV-Gfa2-eGFP injection. Quantification results show that
most eGFP ⫹ cells were GFAP ⫹ astrocytes (62.8 ⫾ 3.4% of all
GFP ⫹ cells in uninjured tissue, 91.5 ⫾ 1.0% in injured tissue),
while only a small percentage of eGFP ⫹ cells were cells of the
oligodendrocytes lineage (18.5 ⫾ 0.8% in uninjured tissue, 6.2 ⫾
0.5% in injured tissue) or neurons (4.2 ⫾ 2% in uninjured tissue,
3.5 ⫾ 0.7% in injured tissue; Fig. 4E). Interestingly, expression in
astrocytes was especially pronounced in the injured spinal cord

(i.e., 91.5% of transduced cells and greater eGFP intensity), likely
due to the intense activation of the Gfa2 promoter following CNS
trauma. High-magnification confocal images further show eGFP
colocalization with GFAP, but not with Olig2 or NeuN (Fig. 4F ).
These results demonstrate that exogenous gene delivered by
AAV-Gfa2 vector was specifically expressed in astrocytes in our
SCI animal model and that AAV-Gfa2-GLT1 injection significantly increased the intraspinal expression of GLT1 protein in the
cervical ventral horn.
Intraspinal GLT1 overexpression in astrocytes increased
PhMN loss following cervical-contusion SCI
Given that astrocyte GLT1 overexpression could be successfully
achieved via intraspinal AAV delivery, we sought to determine
whether GLT1 overexpression would exert beneficial effects on
lesion size and motor neuron loss. We injected AAV-Gfa2-eGFP
or AAV-Gfa2-GLT1 into rats 10 d before C4 contusion (Figs. 3A,
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5A). These pretreatment injections with
AAV were used to provide maximum
transduction and GLT1 overexpression in
the cervical spinal cord by the time of
injury.
When animals were killed at 6 weeks
postinjury, overall spinal cord architecture showed greater damage in AAVGfa2-GLT1 rats (Fig. 5C) than in the
control group receiving AAV-Gfa2-eGFP
(Fig. 5B). Histological analysis on the ipsilesional side of the spinal cord revealed
greater lesion area (in both white and gray
matter) at a number of rostral– caudal distances surrounding the epicenter ( p ⬍
0.01; Fig. 5D), greater rostral– caudal lesion extension (Fig. 5E), and increased
overall lesion volume ( p ⬍ 0.001; Fig. 5F )
in AAV-Gfa2-GLT1 animals compared
with the AAV-Gfa2-eGFP group. We
counted neuron numbers with cresyl violet staining (Fig. 5C, inset) at specific distances from the epicenter on the side
ipsilateral to the injury. Compared with
the control group, GLT1 overexpression
resulted in significantly reduced numbers
of cervical neurons, including both large
motor neurons (Fig. 5G, top graph) and
medium-sized nonmotor neurons (Fig.
5G, bottom graph), at multiple distances
from the lesion epicenter ( p ⬍ 0.05).
Nearly all neurons were lost in both
groups (Fig. 5G) very close to the epicenter in our relatively severe contusion
model (Nicaise et al., 2012a, 2013), which
prevented us from ascertaining the effects
of GLT1 overexpression on motor neuron
loss at these locations.
To specifically evaluate effects on the
phrenic nucleus, we retrogradely labeled
PhMNs by injecting CT␤ into the ipsilateral hemidiaphragm. This approach confirmed that AAV gene delivery spatially
targeted astrocytes surrounding CT␤ ⫹
PhMNs (Fig. 5H ). We analyzed CT␤ labeling in both longitudinal (Fig. 5 I, K )
and transverse (Fig. 5 J, L) spinal cord sections. Increased rostral– caudal extent of
4

Figure 5. Intraspinal GLT1 overexpression in astrocytes increased PhMN loss following cervical-contusion SCI. A, AAV-Gfa2eGFP or AAV-Gfa2-GLT1 was intraspinally injected into rats 10 d before C4-contusion SCI. B, C, Representative images of cresyl
violet staining illustrate the lesion epicenter in AAV-Gfa2-eGFP (B) and AAV-Gfa2-GLT1 (C) groups. D–F, Lesion size (D), rostral–
caudal distance of lesion spread (E), and total lesion volume (F ) were increased in AAV-Gfa2-GLT1 rats compared with AAV-Gfa2eGFP animals. Neuronal populations in the ipsilateral ventral horn were identified (C, inset), quantified, and plotted at multiple
distances from epicenter (G, top, large motor neuron numbers; bottom, medium-sized neuron numbers). To specifically visualize
PhMNs, CT␤ retrograde tracer was injected into the ipsilateral hemidiaphragm. H, Targeting of phrenic nucleus by AAV injections
was assessed by visualization of both AAV-Gfa2-eGFP and CT␤. I–L, Representative images show longitudinal (I, K ) and transverse
(J, L) sections of the cervical spinal cord from AAV-Gfa2-eGFP and AAV-Gfa2-GLT1 pretreated rats, revealing ipsilateral labeling of

CT␤⫹ PhMNs. Injury epicenter is denoted by white asterisk.
Loss of CT␤-labeled cells was greater at the rostral C3 (I–L)
and caudal C5 (data not shown) boundaries of the lesion in the
AAV-Gfa2-GLT1 group (K, L) compared with the AAV-Gfa2eGFP group (I, J). M, Quantification of CT␤-labeled cells shows
significant loss of PhMNs at multiple distances from the epicenter. N, Increased loss of total CT␤-labeled PhMNs was
observed in the AAV-Gfa2-GLT1 group compared with the
AAV-Gfa2-eGFP group. Results were expressed as means ⫾
SEM. *p ⬍ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001 AAV-Gfa2-GLT1
group versus AAV-Gfa2-eGFP group. n ⫽ 11 rats per group for
lesion size analysis and total motor neuron counting; n ⫽ 4
rats per group for CT␤ ⫹ PhMN counting.
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PhMN loss was observed in the AAVGfa2-GLT1 group (Fig. 5K ), with the rostral population of PhMNs located at
C3–C4 being particularly affected. As previously reported in rats (Mantilla et al.,
2009; Nicaise et al., 2012a), PhMNs are
concentrated within compact groups of
cells forming a linear column throughout
the ventromedial region of the C3–C5
ventral horn. Although both AAV groups
showed similar PhMN loss at the epicenter, increased survival of CT␤ ⫹ cells was
found in the most rostral (Fig. 5 I, J, white
arrowheads) and caudal (data not shown)
aspects of the cervical region in AAVGfa2-eGFP rats. Only sparse CT␤ ⫹ cells
were observed in the rostral region of
AAV-Gfa2-GLT1 rats (Fig. 5L). Quantification at multiple distances from the
lesion epicenter further demonstrated
greater PhMN loss in the AAV-Gfa2-GLT1
group compared with AAV-Gfa2-eGFP
(Fig. 5M). Increased PhMN degeneration
was also quantified by estimating the total
number of CT␤ ⫹ PhMNs across the C3–C5
region (ipsilateral to the injury) in the two
AAV-injected groups (p ⬍ 0.05; Fig. 5N).
In summary, these histological results
demonstrate that GLT1 overexpression in
astrocytes of the ventral horn increased lesion size, total motor neuron loss, and
specifically PhMN loss following cervical
contusion SCI.

Figure 6. Intraspinal GLT1 overexpression worsened phrenic nerve axonal degeneration and diaphragm denervation. A,
Phrenic nerve axonal degeneration was observed in both AAV-Gfa2-eGFP and AAV-Gfa2-GLT1 pretreated rats. B, Quantification of
axonal density revealed a decreased number of intact fibers in the AAV-Gfa2-GLT1 group compared with the AAV-Gfa2-eGFP
group. Diaphragm NMJs were assessed via labeling with Alexa-647-conjugated ␣-bungarotoxin (red), SMI-312R (green), and
SV2-s (green). C–E, While areas of muscle denervation were observed in both AAV-Gfa2-eGFP (C) and AAV-Gfa2-GLT1 (D, E)
groups, reduced numbers of intact NMJs and more widespread areas of denervated NMJs were detected in the AAV-Gfa2-GLT1
group. F–H, NMJ morphology analysis was divided into a number of established phenotypic categories: intact (F, asterisk), fully
denervated (G, arrow), partially denervated (F, G, arrowheads), multiply innervated (H, double asterisk), and preterminal axon
thinning. I, For analysis, the hemidiaphragm was divided into three anatomical regions (ventral, medial, and dorsal). C, Ipsilateral
hemidiaphragm from the AAV-Gfa2-eGFP group showed milder NMJ abnormalities. J, In the AAV-Gfa2-GLT1-injected rats, we
observed a reduced percentage of intact NMJs compared with AAV-Gfa2-eGFP-injected rats, regardless of the area examined. D, E,
K, Compared with the ventral portion of the muscle in the AAV-Gfa2-GLT1 group (D), medial and dorsal locations in these same
AAV-Gfa2-GLT1 animals were particularly affected (E), displaying a greater percentage of fully denervated NMJs (K). L, M, The
percentages of NMJs exhibiting partial denervation (L) or multiple innervation (M) were similar between the two groups. N,
The percentage of NMJs with signs of preterminal axon thinning was significantly reduced in the AAV-Gfa2-GLT1 group only at the
dorsal region. Results were expressed as means ⫾ SEM. *p ⬍ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001 AAV-Gfa2-GLT1 group versus
AAV-Gfa2-eGFP group. n ⫽ 11 rats per group for phrenic nerve analysis; n ⫽ 5 rats per group for NMJ analysis.

Intraspinal GLT1 overexpression
worsened phrenic nerve axonal
degeneration and diaphragm
denervation
We next attempted to correlate central
changes observed in the cervical spinal
cord with peripheral pathology at the level
of both the phrenic nerve and diaphragm
NMJ. Anterograde degeneration in the
phrenic nerve was more pronounced in
the AAV-Gfa2-GLT1 group than in the
AAV-Gfa2-eGFP group (Fig. 6A). Quantification of axon density confirmed a significant exacerbation of motor axon loss
with AAV-Gfa2-GLT1 (Fig. 6B). To determine whether greater PhMN loss resulted
in pathological alterations at the diaphragm NMJ, hemidiaphragm muscle
was examined. While areas of muscle
denervation were observed in both
AAV-Gfa2-eGFP (Fig. 6C) and AAVGfa2-GLT1 (Fig. 6 D, E) groups, reduced
numbers of intact NMJs and more widespread areas of denervated NMJs were detected in the AAV-Gfa2-GLT1 group. To
specifically characterize the types of pathological changes occurring, NMJ morphology analysis was divided into a
number of established phenotypic catego-
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ries: intact (Fig. 6F, asterisk), fully denervated (Fig. 6G, arrow), partially denervated (Fig. 6 F, G, arrowheads), multiply
innervated (Fig. 6H, double asterisk), and
preterminal axon thinning. For analysis,
the hemidiaphragm was divided into
three anatomical regions (ventral, medial,
and dorsal; Fig. 6I ), as the rostrocaudal
axis of the PhMN pool topographically
maps onto the ventrodorsal axis of the diaphragm (Laskowski and Sanes, 1987).
Ipsilateral hemidiaphragm from the
AAV-Gfa2-eGFP group showed milder
NMJ abnormalities (Fig. 6C), to an extent
consistent with our previous findings of
C4-contusion SCI alone (Nicaise et al.,
2012a). In the AAV-Gfa2-GLT1-injected
rats, we observed a reduced percentage of
intact NMJs compared with AAV-Gfa2eGFP, regardless of the area examined
( p ⬍ 0.01 for ventral and medial regions,
p ⬍ 0.05 for dorsal region; Fig. 6J ). Compared with the ventral portion of the muscle in the AAV-Gfa2-GLT1 group (Fig.
6D), medial and dorsal locations in these
same AAV-Gfa2-GLT1 animals were particularly affected (Fig. 6E), displaying a
greater percentage of fully denervated
NMJs ( p ⬍ 0.01; Fig. 6K ). The percentages of NMJs exhibiting partial denervation (Fig. 6L) or multiple innervation
(Fig. 6M ) were similar between the two
groups. The percentage of NMJs with
signs of preterminal axon thinning was
significantly reduced in the AAV-Gfa2GLT1 group only at the dorsal region ( p ⬍
0.05; Fig. 6N ). These muscle histology
findings show that PhMN degeneration
due to central GLT1 overexpression in the
cervical spinal cord resulted in severe
pathological effects at the diaphragm
NMJ.

Figure 7. Intraspinal GLT1 overexpression worsened both diaphragmatic and forelimb motor dysfunction. Forelimb motor
performance was assessed weekly by grip strength testing of the ipsilateral (right) forelimb and the paw preference test. A, Grip
strength testing revealed a slight recovery in the AAV-Gfa2-eGFP group, which was not observed in the AAV-Gfa2-GLT1 group. B,
The cylinder paw preference test demonstrated a drastic reduction in use of the ipsilateral forepaw for both injury groups during the
first week postinjury, followed by a significant recovery in only the AAV-Gfa2-eGFP group. Functional innervation of the ipsilateral
hemidiaphragm was evaluated using phrenic nerve conduction studies. C, Diaphragm CMAPs obtained following supramaximal
stimulation (arrows show time of stimulation) were recorded in the ipsilateral hemidiaphragm and showed reduced amplitude for
both groups. CMAP amplitudes were ⬃8 mV in uninjured laminectomy-only rats. D, E, Compared with AAV-Gfa2-eGFP, peak
CMAP amplitudes were significantly reduced with AAV-Gfa2-GLT1 injection at 2 (D) and 14 (E) DPI. F, G, Spontaneous diaphragm
EMG recordings from AAV-Gfa2-eGFP (F) and AAV-Gfa2-GLT1 (G) groups are shown as raw voltage output (F, G, top) and integrated signals (F, G, bottom). H–J, Inspiratory burst duration (H), inspiratory bursts per minute (I), and integrated EMG amplitude
(J) in the ipsilateral hemidiaphragm were averaged over a 2 min sample period. Results were expressed as means ⫾ SEM. *p ⬍
0.05, **p ⬍ 0.01 AAV-Gfa2-GLT1 group versus AAV-Gfa2-eGFP group. n ⫽ 11 rats per group for assessment of forelimb motor
function; n ⫽ 5–7 rats per group for CMAP recordings; n ⫽ 4 rats per group for EMG recordings.

Intraspinal GLT1 overexpression
worsened both diaphragmatic and
forelimb motor dysfunction
It is important to characterize the in vivo
functional effects of AAV-based GLT1
overexpression on both forelimb motor
and diaphragmatic function, given that the motor neuron populations innervating these muscles are located in the cervical
spinal cord and are profoundly affected by human cervical
SCI. We monitored forelimb motor function after cervical
contusion weekly for 6 weeks postinjury using grip strength
testing and the paw preference/cylinder test. While both AAV
groups were chronically impaired up to 42 DPI compared with
preinjury baseline, AAV-Gfa2-eGFP animals showed signs of
partial grip strength recovery at several time points postinjury
compared with AAV-Gfa2-GLT1 rats ( p ⬍ 0.05 at 21, 28, and
42 DPI; Fig. 7A). This finding was accompanied by an increased use of ipsilateral forelimb in the cylinder test in the
AAV-Gfa2-eGFP group ( p ⬍ 0.05 at 21 and 35 DPI, p ⬍ 0.01 at
42 DPI; Fig. 7B).

In parallel, we electrophysiologically investigated functional
innervation of the diaphragm by PhMNs using phrenic nerve
conduction studies. Following supramaximal phrenic nerve
stimulus, we obtained CMAP recordings from the surface of the
ipsilateral hemidiaphragm. In both groups, peak CMAP amplitude was significantly reduced compared with uninjured
laminectomy-only animals (Fig. 7C), whose CMAP amplitudes
were ⬃8 mV (data not shown), consistent with our previous
findings in this SCI model (Nicaise et al., 2012a). However,
CMAP amplitudes in AAV-Gfa2-GLT1 animals were significantly reduced compared with AAV-Gfa2-eGFP at both 2 DPI
(Fig. 7D) and 14 DPI (Fig. 7E). Spontaneous diaphragm EMG
recordings at 35 DPI from AAV-Gfa2-eGFP (Fig. 7F ) and AAVGfa2-GLT1 (Fig. 7G) groups showed no changes in the duration
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caudal extension of the lesion (Fig. 8C),
lesion volume (Fig. 8D), total motor
neuron counts (Fig. 8E), or phrenic
nerve axonal loss (Fig. 8F ) at 35 DPI.
Given the lack of differences in a number of histological tests, we did not conduct CT␤ or NMJ analyses on these
animals. We also conducted functional
examination of forelimb motor and diaphragmatic function in the acute injection paradigm. Similar to histological
analyses, no differences between groups
were noted in ipsilateral forelimb grip
strength (Fig. 8G), ipsilateral forelimb
use in the cylinder test (Fig. 8H ), or diaphragm CMAP amplitude at 35 DPI
(Fig. 8I ).
Last, we also tested delayed injection of
AAV vectors at 7 DPI, again using the exact same SCI model as pretreatment and
“acute” injection paradigms. With delayed injection of AAV-Gfa2-eGFP and
AAV-Gfa2-GLT1, we observed no effects
of GLT1 overexpression on lesion measurements, total motor neuron or PhMN
loss, diaphragm denervation, or forelimb
Figure 8. Intraspinal GLT1 gene delivery at the time of cervical-contusion SCI did not affect histological or functional outcomes. motor function using histological and
AAV-Gfa2-eGFP or AAV-Gfa2-GLT1 vector was intraspinally injected into rats immediately following C4 contusion. A, Animals were
functional measures (data not shown).
killed 35 DPI. B–F, Lesion size (B), rostral– caudal extension of the lesion (C), total lesion volume (D), ipsilateral total motor neuron
Unlike the results obtained with precounts (E), and axon density in the ipsilateral phrenic nerve (F) did not significantly differ between groups. G, H, No differences
treatment,
our findings with “acute”
were noted between groups with grip strength testing (G) or the cylinder paw preference test (H). I, Diaphragm CMAP amplitudes
did not differ between groups. Results were expressed as means ⫾ SEM. *p ⬍ 0.05, **p ⬍ 0.01 AAV-Gfa2-GLT1 group versus injection and injection at 7 DPI demonAAV-Gfa2-eGFP group. n ⫽ 5 rats per group for lesion size analysis and total motor neuron counting; n ⫽ 9 rats per group for strate that AAV-GLT1 delivery soon after
injury does not modify outcome. These
phrenic nerve analysis, assessment of forelimb motor function, and CMAP recordings.
results are likely due to the temporal delay
involved in achieving transduction and
of each discharge (Fig. 7H ), while the number of inspiratory
GLT1 overexpression with intraspinal AAV injection (Fig. 3B). If
bursts per minute was significantly increased in the AAV-Gfa2GLT1 overexpression is to be targeted at early time points postGLT1 group compared with control group (Fig. 7I ). The inteSCI, an alternative strategy to viral vector delivery is likely needgrated EMG amplitude in the AAV-Gfa2-GLT1 group was
ed; however, intraspinal injection immediately after injury (or
slightly reduced compared with the control group; however, this
even at very early time points) will likely not be a practically
difference was not statistically significant (Fig. 7J ).
feasible approach for patients. Last, the difference in results beThese results demonstrate that increased cervical motor neutween pretreatment and acute/delayed delivery paradigms sugron loss and diaphragm denervation associated with astrocyte
gests that the negative effects of GLT1 overexpression are based
GLT1 overexpression resulted in an actual in vivo worsening of
on events occurring during the initial hours to days post-trauma.
diaphragm and forelimb motor dysfunction in our clinically relevant model of cervical-contusion SCI.
Overexpression of GLT1 reduced astrocyte proliferation and
migration, altered astrocyte morphology in vitro, and
Intraspinal GLT1 gene delivery at the time of cervicalcompromised astroglial scar border formation in vivo
contusion SCI did not affect histological or functional
To determine the phenotypic effects of GLT1 overexpression on
outcome
astrocytes, we performed an in vitro scratch-wound assay and
We next sought to determine the effects of AAV-Gfa2-GLT1 gene
also analyzed astroglial scar formation in vivo following cervical
delivery at an “acute” time point by injecting virus immediately
contusion SCI to study the protective scar-forming capacity of
following unilateral cervical contusion using the exact same SCI
astrocytes in response to injury. For the in vitro scratch-wound
model (Fig. 8A). AAV pretreatment represents a powerful apassay, wound/gap area, astrocyte migration to various distances
proach for testing proof of principle because it allows for maxiwithin the scratch site (D ⬍ 150 m or D ⬎ 150 m), cell promal GLT1 overexpression by the time of injury, even if it is not
liferation surrounding the wound site, and process length of midirectly relevant to clinical translation. In contrast, the acute ingrating cells were assessed 24 h after scratch injury to an astrocyte
jection strategy is a delivery paradigm directly relevant to the
monolayer was induced (Fig. 9A). Quantification results showed
potential treatment of cervical SCI patients. Using the same histhat overexpression of GLT1 using AAV-Gfa2-GLT1 slowed
tological analyses employed for the AAV pretreatment studies, we
wound healing (Fig. 9B), reduced astrocyte migration (Fig. 9C)
characterized the effects of AAV-Gfa2-eGFP and AAV-Gfa2and proliferation (Fig. 9D), and shortened the process of migratGLT1 following acute injection. There were no significant difing astrocytes (Fig. 9E). For the in vivo astroglial scar border
ferences between virus types in lesion size (Fig. 8B), rostral–
formation analysis, immunostaining with anti-GFAP antibody
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Figure 9. Overexpression of GLT1 reduced astrocyte proliferation and migration, altered astrocyte morphology in vitro, and compromised astroglial scar border formation in vivo. A, For the in vitro
scratch-wound assay, wound/gap area, astrocyte migration to various distances within the scratch site (D ⬍ 150 m or D ⬎ 150 m), cell proliferation surrounding the wound site, and process
length of migrating cells were assessed 24 h after scratch injury was induced. B–E, Quantification results showed that overexpression of GLT1 slowed wound healing (B), reduced astrocyte migration
(C) and proliferation (D), and shortened the process of migrating astrocytes (E). F, For the in vivo astroglial scar border formation analysis, immunostaining with anti-GFAP antibody was performed
3 weeks after injury in the AAV pretreatment delivery paradigm. G, Quantification results show that astroglial scar border formation (F, yellow solid line) in the AAV-Gfa2-GLT1 group was significantly
reduced compared with the AAV-Gfa2-eGFP group. H, GFAP signal intensity of the scar border (F, red selection, a) in the AAV-Gfa2-GLT1 group was significantly reduced compared with the
AAV-Gfa2-eGFP group, while in the area next to the border (F, red selection, a⬘) GFAP signal intensity was similar between the two groups. Results were expressed as means ⫾ SEM. *p⬍0.05,
**p ⬍ 0.01, ***p ⬍ 0.001. n ⫽ 5–7 per group for in vitro assay, n ⫽ 12–13 per group for in vivo analysis.

was performed 3 weeks after injury (Fig. 9F ) in the pretreatment
virus delivery paradigm. Quantification results show that astroglial scar border formation (Fig. 9F, yellow solid line) in the AAVGfa2-GLT1 group was significantly reduced compared with the
AAV-Gfa2-eGFP group (Fig. 9G). In addition, GFAP signal intensity of the astrocyte scar border (Fig. 9F, red selection: a) in the
AAV-Gfa2-GLT1 group was significantly reduced compared
with the AAV-Gfa2-eGFP group, while in the area next to the
border (Fig. 9F, red selection: a⬘) GFAP signal intensity was similar between the two groups (Fig. 9H ). These data show that
GLT1 overexpression resulted in a compromised astrogliotic response both in vitro and in vivo, including altered morphology
and reduced proliferation, in vitro wound healing, and in vivo
scar border formation. These results shed greater light on why
GLT1 overexpression in astrocytes worsens outcome in following
cervical-contusion SCI model.

Discussion
In the context of SCI, astrocyte reactivity has traditionally been
viewed negatively in association with the astroglial scar and its
inhibitory effects on axon regeneration/plasticity. However, astrocytes normally play an integral role in the CNS via a number of
important functions (Pekny and Nilsson, 2005). The astrocyte
response following SCI should not be approached only as a dichotomy of quiescent versus reactive, but should be viewed as
occurring along a spectrum of phenotypes, depending on type,
location, timing, and severity of the insult (Sofroniew, 2005).
Importantly, it is crucial to study specific astrocyte functions in
the diseased nervous system, not just to generalize an astrocyte
response. Along these lines, we observed both early and persistent
GLT1 expression loss in ventral horn astrocytes following cervical
contusion. These findings are in line with previous work from
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our group (Lepore et al., 2011a, 2011c) and from others (VeraPortocarrero et al., 2002; Olsen et al., 2010) demonstrating GLT1
downregulation following thoracic SCI. We also observed pronounced and persistent astrocyte reactivity and even proliferation of some of these cells. Despite this robust response that
resulted in increased astrocyte numbers, there were significantly
reduced numbers of GLT1-expressing cells as a large portion of
the astrocyte population did not express GLT1.
Intraspinal glutamate levels dramatically and rapidly increase
following SCI (Panter et al., 1990). Glutamate, when present in
excess and/or for too long, is deleterious in vitro and in vivo for
neurons and oligodendrocytes (Xu et al., 2008). Riluzole, an “antiglutamatergic” compound whose mechanism of action is not
fully understood, improves outcome in a cervical SCI model (Wu
et al., 2013). These data suggest that targeting extracellular glutamate dysregulation is a rational strategy for attenuating secondary damage. Even though secondary degeneration is relatively
protracted following SCI, temporal dynamics of this process vary
across cell types. We previously demonstrated that PhMNs are
lost mostly during the first day after cervical contusion (Nicaise et
al., 2013), suggesting that early GLT1 downregulation we observed is relevant to PhMN protection/loss, while persistent decrease in GLT1 is likely more relevant to other SCI outcomes,
such as delayed oligodendrocyte injury (Park et al., 2004) and
neuronal hyperexcitability (Gwak and Hulsebosch, 2011). Therefore, we chose to test GLT1 overexpression at early time points
after injury for PhMN protection.
To test this hypothesis, we delivered exogenous GLT1 to cervical spinal cord using AAV serotype-8, a nontoxic method (Ponnazhagan et al., 1997; Monahan et al., 2002). As GLT1 is
predominantly expressed in astrocytes (Maragakis and Rothstein, 2004), we generated vectors in which the exogenous gene
was driven by the GFAP promoter. Considering the delay involved in achieving efficient in vivo virus transduction and subsequent protein expression, we delivered virus using three
different temporal paradigms: (1) injection at 10 d preinjury to
assure that GLT1 expression was increased by the time of injury;
(2) injection immediately after injury; (3) injection at 7 DPI.
We found no differences between the two virus groups in both
the second or third injection paradigms, which is likely because
the majority of PhMN loss occurs within the first 24 h after contusion (Nicaise et al., 2013). Surprisingly, we found that pretreatment and consequent GLT1 overexpression at the time of and
following injury exacerbated PhMN degeneration and diaphragm dysfunction. While the pretreatment temporal delivery
paradigm is not directly relevant for therapy, these exciting findings are still very important for understanding the effects of modulating GLT1 function following SCI using viral or other
therapeutic approaches. These findings are in contrast to work
showing that partial knockdown in the thoracic crush SCI model
using GLT1 heterozygous mice exacerbates lesion spreading and
motor deficits (Lepore et al., 2011c). It is possible that reactive
astrocytes are not optimal targets for GLT1 overexpression, particularly without modulating overall reactive state of the astrocyte. For example, crush-type SCI also induces astrocyte Kir4.1
potassium channel downregulation (Olsen et al., 2010), which
may indirectly affect exogenously expressed GLT1 given the interplay between intracellular/extracellular ion homeostasis and
GLT1 function. It therefore may not be enough to just increase
GLT1 expression; instead, this approach may need to be conducted in the context of physiologically “healthy” astrocytes.
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Along these lines, our observations may be explained by reverse transport. Under such conditions as inversion of the electrochemical gradients of Na ⫹ and K ⫹ (Grewer et al., 2008),
GLT1 can release glutamate into the extracellular space, thereby
increasing neuron and oligodendrocyte damage (Matute et al.,
2007; Gouix et al., 2009). Hemorrhage, edema, and ischemia can
appear within minutes to hours of CNS trauma (Carlson and
Gorden, 2002), resulting in GLT1 reversal and consequent glutamate receptor-mediated toxicity (Szatkowski and Attwell, 1994).
In our experiments, more GLT1 would be available for such a
mechanism. This would be partly consistent with results of ischemic injury. At early stages (i.e., 5 min), ischemia-induced glutamate levels in hippocampus of wild-type mice are significantly
lower than those in mice lacking GLT1, while after 20 min of
ischemia, glutamate levels in wild-type mice are double those of
GLT1 heterozygotes (Mitani and Tanaka, 2003). These results
suggest that GLT1 forward transport plays a role in uptake at
early stages, while reverse transport may subsequently predominate for some period of time, depending on specifics of the insult
(Szatkowski and Attwell, 1994). Since neuron death caused by
oxygen-glucose deprivation preconditioning is relieved by downregulating (Wang et al., 2013) or inhibiting (Kosugi and Kawahara, 2006) GLT1, the combination of GLT1 overexpression and
selective inhibition of reverse transport may be a successful approach. Unlike the commonly used GLT1 inhibitors DL-threo␤-benzyloxyaspartate (Colleoni et al., 2008) and DHK
(Shirasaki et al., 2010), which target both forward and reverse
transport, bromocriptine (Shirasaki et al., 2010) and (⫺-3hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]-isoxazole4-carboxylic acid (Colleoni et al., 2008) are thought to mainly
inhibit reverse transport.
Astrocytes are more resistant to ischemic injury than neurons
(Goldberg and Choi, 1993), possibly because of larger glycogen
stores (Cataldo and Broadwell, 1986; Brown and Ransom, 2007)
and reduced susceptibility to excitotoxicity (Choi and Rothman,
1990). However, in severe ischemic conditions, loss of the
Na ⫹/K ⫹ gradient across the astrocyte plasma membrane can
result in astrocyte death in the presence of glutamate (Rossi et al.,
2007; Szydlowska et al., 2010). It has been reported that GLT1
reverse transport promotes astrocyte survival by maintaining low
intracellular concentrations of Na ⫹ and Ca 2⫹ (Kosugi and
Kawahara, 2006). In our experiments, GLT1 overexpression may
further promote survival of reactive astrocytes. However, chronic
astrocyte reactivity may result in a phenotypic switch to a detrimental population. These highly reactive astrocytes could release
nitric oxide and reactive oxygen species (Bal-Price and Brown,
2001) that modulate glutamate receptors and consequently lead
to damage (Stewart et al., 2002). These cells may also release a
variety of cytokines, including TNF␣, that are toxic to oligodendrocytes and inhibit neurite outgrowth (D’Souza et al., 1996;
Neumann et al., 2002). CCL2, CCL5, and CXCL8 release could
also recruit immune cells, leading to inflammatory damage (Oh
et al., 1999).
After CNS trauma, areas of focal damage are surrounded by an
astroglial scar that separates necrotic from spared tissue (Kawano
et al., 2012). Transgenic ablation of the proliferating astrocytes
that contribute to this process post-SCI leads to increased
inflammation, demyelination, lesion volume, and neuronal
loss (Faulkner et al., 2004). The glial scar is formed, in part, by
proliferating elongated astrocytes. Similarly, when cocultured in
vitro with inflammatory cells, astrocytes display bipolar or radial
morphologies with elongated processes, and segregate macrophages into discrete clusters (Wanner et al., 2013). In an in vitro

7636 • J. Neurosci., May 28, 2014 • 34(22):7622–7638

scratch-wound experiment using astrocyte cultures, we found
that GLT1 overexpression reduced astrocyte migration and proliferation, and altered astrocyte morphology such that they displayed shortened processes compared with cells transduced with
control virus. Furthermore, in vivo scar formation analysis
showed that astroglial scar border formation was significantly
compromised in the AAV-GLT1 compared with the control
AAV-eGFP group following cervical-contusion SCI. These findings suggest that alteration of the protective scar-forming capacity of astrocytes may be one possible mechanism for the
detrimental effects of GLT1 overexpression.
Beneficial effects of GLT1 have been reported in other CNS
disease models. For example, GLT1 overexpression reduces ischemic brain injury in a rat stroke model (Harvey et al., 2011).
GLT1 knockdown exacerbates hippocampal neuronal damage
following traumatic brain injury (Rao et al., 2001). Intraspinal
gene transfer of GLT1 attenuates inflammatory and neuropathic
pain in rats (Maeda et al., 2008). The discrepancy with our data
may be explained, for example, by disease-specific pathological
conditions and different spatiotemporal GLT1 expression
patterns.
We did not detect motor neuron toxicity or functional impairment with AAV injection into uninjured spinal cord or in the
“acute” or “delayed” paradigms postinjury. We found worsening
in the pretreatment paradigm only with AAV-GLT1. We observed robust and mostly astrocyte-specific transduction that resulted in significantly increased intraspinal GLT1 expression,
with very little ectopic expression in nonastrocyte populations.
Last, we found increased functional glutamate uptake with AAVGLT1, demonstrating that transduction resulted in not only protein overexpression but correct membrane localization and
transporter function. Together, these results suggest that the observed negative effects were due to increased GLT1 expression in
astrocytes and not to the injection procedure, AAV vector, or
expression of nonfunctional transporter.
Despite the current results, we still believe that increasing
GLT1 is a potentially useful approach. Further studies need to
determine the target astrocyte population(s) and correct timing
of delivery. Importantly, our findings demonstrate that this
AAV-based strategy allows for efficient and long-term gene delivery to spinal cord astrocytes. Furthermore, this anatomically
specific approach is crucial for avoiding unwanted side effects.
Although AMPA and NMDA antagonists have shown promise
for SCI (Wrathall et al., 1994; Agrawal and Fehlings, 1997; Rosenberg et al., 1999; Gaviria et al., 2000), therapeutically targeting
glutamate receptor overactivation has diffuse and nonspecific effects in CNS, PNS, and potentially other tissues, as well as only a
short temporal duration (Bleakman et al., 2006).
Studies need to model clinically relevant aspects of human
SCI. Despite the predominance of cervical contusion in patients,
therapies targeting protection of respiratory circuitry have not
been extensively tested in appropriate models. The data presented illustrate how our cervical-contusion model and set of
histological and functional analyses represents a powerful approach for understanding and treating SCI.
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